Increased levels of 5‐HT1A receptor binding in ventral visual pathways in Parkinson's disease
Identifieur interne : 001413 ( Main/Exploration ); précédent : 001412; suivant : 001414Increased levels of 5‐HT1A receptor binding in ventral visual pathways in Parkinson's disease
Auteurs : Philippe Huot [Canada] ; Tom H. Johnston [Canada] ; Naomi P. Visanji [Canada] ; Tayyeba Darr [Canada] ; Donna Pires [Canada] ; Lili-Naz Hazrati [Canada] ; Jonathan M. Brotchie [Canada] ; Susan H. Fox [Canada]Source :
- Movement Disorders [ 0885-3185 ] ; 2012-05.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
- 5-HT1A Serotonine receptor, 5‐HT1A receptors, Aged, Aged, 80 and over, Antiparkinson Agents (therapeutic use), Autoradiography, Brain (metabolism), Female, Hallucinations (complications), Hallucinations (metabolism), Humans, Levodopa, Levodopa (therapeutic use), L‐dopa, Male, Nervous system diseases, Parkinson Disease (complications), Parkinson Disease (drug therapy), Parkinson Disease (metabolism), Parkinson disease, Parkinson's disease, Receptor, Serotonin, 5-HT1A (metabolism), Serotonin, Visual Pathways (metabolism), Visual hallucination, Visual pathway, serotonin, visual hallucinations.
- MESH :
- chemical , metabolism : Receptor, Serotonin, 5-HT1A.
- chemical , therapeutic use : Antiparkinson Agents, Levodopa.
- complications : Hallucinations, Parkinson Disease.
- drug therapy : Parkinson Disease.
- metabolism : Brain, Hallucinations, Parkinson Disease, Visual Pathways.
- Aged, Aged, 80 and over, Autoradiography, Female, Humans, Male.
Abstract
Visual hallucinations are common in advanced Parkinson's disease (PD). The pathophysiology of visual hallucinations may involve enhanced serotonergic neurotransmission. The atypical antipsychotics clozapine and quetiapine, which have affinity for 5‐HT2A and 5‐HT1A receptors, are effective against visual hallucinations in PD. 5‐HT2A receptors are increased in ventral visual pathways in PD patients with visual hallucinations, and we hypothesized that 5‐HT1A receptors were also involved in visual hallucinations in PD. Autoradiographic binding using [3H]‐WAY‐100,635 and NAN‐190 was performed in brain sections from 6 PD patients with visual hallucinations, 6 PD patients without visual hallucinations, and 5 age‐matched controls. All PD subjects had been treated with L‐dopa. Brain areas studied were the orbitofrontal, inferolateral temporal, and motor cortices, as well as the striatum, globus pallidus, substantia nigra, and thalamus. 5‐HT1A‐binding levels were dramatically increased in the ventral visual pathways of all PD patients compared with controls (0 vs 11 and 0 vs 100 nmol/mg, respectively; both P < .05). There was no significant difference in 5‐HT1A‐binding levels in PD patients with visual hallucinations compared with PD patients without visual hallucinations or with controls in any of the brain areas studied (P > .05). Gross abnormalities in 5‐HT1A levels in ventral visual areas occurred in all PD patients exposed to L‐dopa. However, as there was no difference in 5‐HT1A‐binding levels between hallucinators and nonhallucinators, alterations in 5‐HT1A receptor levels may not contribute specifically to visual hallucinations in PD. However, the discrete anatomical distribution of rises to the ventral visual areas suggests some role in predisposing to visual hallucinations. © 2012 Movement Disorder Society
Url:
DOI: 10.1002/mds.24964
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000C93
- to stream Istex, to step Curation: 000C93
- to stream Istex, to step Checkpoint: 000260
- to stream PubMed, to step Corpus: 000A75
- to stream PubMed, to step Curation: 000A75
- to stream PubMed, to step Checkpoint: 000A75
- to stream Ncbi, to step Merge: 001091
- to stream Ncbi, to step Curation: 001091
- to stream Ncbi, to step Checkpoint: 001091
- to stream Main, to step Merge: 001445
- to stream PascalFrancis, to step Corpus: 000190
- to stream PascalFrancis, to step Curation: 000A62
- to stream PascalFrancis, to step Checkpoint: 000149
- to stream Main, to step Merge: 001563
- to stream Main, to step Curation: 001413
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Increased levels of 5‐HT1A receptor binding in ventral visual pathways in Parkinson's disease</title><author><name sortKey="Huot, Philippe" sort="Huot, Philippe" uniqKey="Huot P" first="Philippe" last="Huot">Philippe Huot</name></author><author><name sortKey="Johnston, Tom H" sort="Johnston, Tom H" uniqKey="Johnston T" first="Tom H." last="Johnston">Tom H. Johnston</name></author><author><name sortKey="Visanji, Naomi P" sort="Visanji, Naomi P" uniqKey="Visanji N" first="Naomi P." last="Visanji">Naomi P. Visanji</name></author><author><name sortKey="Darr, Tayyeba" sort="Darr, Tayyeba" uniqKey="Darr T" first="Tayyeba" last="Darr">Tayyeba Darr</name></author><author><name sortKey="Pires, Donna" sort="Pires, Donna" uniqKey="Pires D" first="Donna" last="Pires">Donna Pires</name></author><author><name sortKey="Hazrati, Lili Az" sort="Hazrati, Lili Az" uniqKey="Hazrati L" first="Lili-Naz" last="Hazrati">Lili-Naz Hazrati</name></author><author><name sortKey="Brotchie, Jonathan M" sort="Brotchie, Jonathan M" uniqKey="Brotchie J" first="Jonathan M." last="Brotchie">Jonathan M. Brotchie</name></author><author><name sortKey="Fox, Susan H" sort="Fox, Susan H" uniqKey="Fox S" first="Susan H." last="Fox">Susan H. Fox</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:20FC845813D16900FCBEF3A57D8CB14CAA08AEB2</idno><date when="2012" year="2012">2012</date><idno type="doi">10.1002/mds.24964</idno><idno type="url">https://api-v5.istex.fr/document/20FC845813D16900FCBEF3A57D8CB14CAA08AEB2/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000C93</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000C93</idno><idno type="wicri:Area/Istex/Curation">000C93</idno><idno type="wicri:Area/Istex/Checkpoint">000260</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000260</idno><idno type="wicri:doubleKey">0885-3185:2012:Huot P:increased:levels:of</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:22419526</idno><idno type="wicri:Area/PubMed/Corpus">000A75</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000A75</idno><idno type="wicri:Area/PubMed/Curation">000A75</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000A75</idno><idno type="wicri:Area/PubMed/Checkpoint">000A75</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000A75</idno><idno type="wicri:Area/Ncbi/Merge">001091</idno><idno type="wicri:Area/Ncbi/Curation">001091</idno><idno type="wicri:Area/Ncbi/Checkpoint">001091</idno><idno type="wicri:Area/Main/Merge">001445</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:12-0248754</idno><idno type="wicri:Area/PascalFrancis/Corpus">000190</idno><idno type="wicri:Area/PascalFrancis/Curation">000A62</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">000149</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000149</idno><idno type="wicri:doubleKey">0885-3185:2012:Huot P:increased:levels:of</idno><idno type="wicri:Area/Main/Merge">001563</idno><idno type="wicri:Area/Main/Curation">001413</idno><idno type="wicri:Area/Main/Exploration">001413</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Increased levels of 5‐HT1A receptor binding in ventral visual pathways in Parkinson's disease</title><author><name sortKey="Huot, Philippe" sort="Huot, Philippe" uniqKey="Huot P" first="Philippe" last="Huot">Philippe Huot</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Toronto Western Research Institute, Toronto Western Hospital, University Health Network, Toronto, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation><affiliation wicri:level="4"><country xml:lang="fr">Canada</country><wicri:regionArea>Division of Neurology, University of Toronto, Movement Disorder Clinic, Toronto, Ontario</wicri:regionArea><orgName type="university">Université de Toronto</orgName><placeName><settlement type="city">Toronto</settlement><region type="state">Ontario</region></placeName></affiliation></author><author><name sortKey="Johnston, Tom H" sort="Johnston, Tom H" uniqKey="Johnston T" first="Tom H." last="Johnston">Tom H. Johnston</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Toronto Western Research Institute, Toronto Western Hospital, University Health Network, Toronto, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation></author><author><name sortKey="Visanji, Naomi P" sort="Visanji, Naomi P" uniqKey="Visanji N" first="Naomi P." last="Visanji">Naomi P. Visanji</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Tanz Centre for Research in Neurodegenerative Diseases, Toronto, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation></author><author><name sortKey="Darr, Tayyeba" sort="Darr, Tayyeba" uniqKey="Darr T" first="Tayyeba" last="Darr">Tayyeba Darr</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Toronto Western Research Institute, Toronto Western Hospital, University Health Network, Toronto, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation></author><author><name sortKey="Pires, Donna" sort="Pires, Donna" uniqKey="Pires D" first="Donna" last="Pires">Donna Pires</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Toronto Western Research Institute, Toronto Western Hospital, University Health Network, Toronto, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation></author><author><name sortKey="Hazrati, Lili Az" sort="Hazrati, Lili Az" uniqKey="Hazrati L" first="Lili-Naz" last="Hazrati">Lili-Naz Hazrati</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Tanz Centre for Research in Neurodegenerative Diseases, Toronto, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation></author><author><name sortKey="Brotchie, Jonathan M" sort="Brotchie, Jonathan M" uniqKey="Brotchie J" first="Jonathan M." last="Brotchie">Jonathan M. Brotchie</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Toronto Western Research Institute, Toronto Western Hospital, University Health Network, Toronto, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation></author><author><name sortKey="Fox, Susan H" sort="Fox, Susan H" uniqKey="Fox S" first="Susan H." last="Fox">Susan H. Fox</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Toronto Western Research Institute, Toronto Western Hospital, University Health Network, Toronto, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation><affiliation wicri:level="4"><country xml:lang="fr">Canada</country><wicri:regionArea>Division of Neurology, University of Toronto, Movement Disorder Clinic, Toronto, Ontario</wicri:regionArea><orgName type="university">Université de Toronto</orgName><placeName><settlement type="city">Toronto</settlement><region type="state">Ontario</region></placeName></affiliation><affiliation wicri:level="1"><country>Canada</country><wicri:regionArea>Movement Disorder Clinic, McL 7‐421, Toronto Western Hospital, 399 Bathurst Street, Toronto, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2012-05">2012-05</date><biblScope unit="volume">27</biblScope><biblScope unit="issue">6</biblScope><biblScope unit="page" from="735">735</biblScope><biblScope unit="page" to="742">742</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">20FC845813D16900FCBEF3A57D8CB14CAA08AEB2</idno><idno type="DOI">10.1002/mds.24964</idno><idno type="ArticleID">MDS24964</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>5-HT1A Serotonine receptor</term><term>5‐HT1A receptors</term><term>Aged</term><term>Aged, 80 and over</term><term>Antiparkinson Agents (therapeutic use)</term><term>Autoradiography</term><term>Brain (metabolism)</term><term>Female</term><term>Hallucinations (complications)</term><term>Hallucinations (metabolism)</term><term>Humans</term><term>Levodopa</term><term>Levodopa (therapeutic use)</term><term>L‐dopa</term><term>Male</term><term>Nervous system diseases</term><term>Parkinson Disease (complications)</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (metabolism)</term><term>Parkinson disease</term><term>Parkinson's disease</term><term>Receptor, Serotonin, 5-HT1A (metabolism)</term><term>Serotonin</term><term>Visual Pathways (metabolism)</term><term>Visual hallucination</term><term>Visual pathway</term><term>serotonin</term><term>visual hallucinations</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Receptor, Serotonin, 5-HT1A</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term><term>Levodopa</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Hallucinations</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Brain</term><term>Hallucinations</term><term>Parkinson Disease</term><term>Visual Pathways</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Aged, 80 and over</term><term>Autoradiography</term><term>Female</term><term>Humans</term><term>Male</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Hallucination visuelle</term><term>Lévodopa</term><term>Maladie de Parkinson</term><term>Pathologie du système nerveux</term><term>Récepteur sérotoninergique 5-HT1A</term><term>Sérotonine</term><term>Voie visuelle</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Visual hallucinations are common in advanced Parkinson's disease (PD). The pathophysiology of visual hallucinations may involve enhanced serotonergic neurotransmission. The atypical antipsychotics clozapine and quetiapine, which have affinity for 5‐HT2A and 5‐HT1A receptors, are effective against visual hallucinations in PD. 5‐HT2A receptors are increased in ventral visual pathways in PD patients with visual hallucinations, and we hypothesized that 5‐HT1A receptors were also involved in visual hallucinations in PD. Autoradiographic binding using [3H]‐WAY‐100,635 and NAN‐190 was performed in brain sections from 6 PD patients with visual hallucinations, 6 PD patients without visual hallucinations, and 5 age‐matched controls. All PD subjects had been treated with L‐dopa. Brain areas studied were the orbitofrontal, inferolateral temporal, and motor cortices, as well as the striatum, globus pallidus, substantia nigra, and thalamus. 5‐HT1A‐binding levels were dramatically increased in the ventral visual pathways of all PD patients compared with controls (0 vs 11 and 0 vs 100 nmol/mg, respectively; both P < .05). There was no significant difference in 5‐HT1A‐binding levels in PD patients with visual hallucinations compared with PD patients without visual hallucinations or with controls in any of the brain areas studied (P > .05). Gross abnormalities in 5‐HT1A levels in ventral visual areas occurred in all PD patients exposed to L‐dopa. However, as there was no difference in 5‐HT1A‐binding levels between hallucinators and nonhallucinators, alterations in 5‐HT1A receptor levels may not contribute specifically to visual hallucinations in PD. However, the discrete anatomical distribution of rises to the ventral visual areas suggests some role in predisposing to visual hallucinations. © 2012 Movement Disorder Society</div></front></TEI><affiliations><list><country><li>Canada</li></country><region><li>Ontario</li></region><settlement><li>Toronto</li></settlement><orgName><li>Université de Toronto</li></orgName></list><tree><country name="Canada"><noRegion><name sortKey="Huot, Philippe" sort="Huot, Philippe" uniqKey="Huot P" first="Philippe" last="Huot">Philippe Huot</name></noRegion><name sortKey="Brotchie, Jonathan M" sort="Brotchie, Jonathan M" uniqKey="Brotchie J" first="Jonathan M." last="Brotchie">Jonathan M. Brotchie</name><name sortKey="Darr, Tayyeba" sort="Darr, Tayyeba" uniqKey="Darr T" first="Tayyeba" last="Darr">Tayyeba Darr</name><name sortKey="Fox, Susan H" sort="Fox, Susan H" uniqKey="Fox S" first="Susan H." last="Fox">Susan H. Fox</name><name sortKey="Fox, Susan H" sort="Fox, Susan H" uniqKey="Fox S" first="Susan H." last="Fox">Susan H. Fox</name><name sortKey="Fox, Susan H" sort="Fox, Susan H" uniqKey="Fox S" first="Susan H." last="Fox">Susan H. Fox</name><name sortKey="Hazrati, Lili Az" sort="Hazrati, Lili Az" uniqKey="Hazrati L" first="Lili-Naz" last="Hazrati">Lili-Naz Hazrati</name><name sortKey="Huot, Philippe" sort="Huot, Philippe" uniqKey="Huot P" first="Philippe" last="Huot">Philippe Huot</name><name sortKey="Johnston, Tom H" sort="Johnston, Tom H" uniqKey="Johnston T" first="Tom H." last="Johnston">Tom H. Johnston</name><name sortKey="Pires, Donna" sort="Pires, Donna" uniqKey="Pires D" first="Donna" last="Pires">Donna Pires</name><name sortKey="Visanji, Naomi P" sort="Visanji, Naomi P" uniqKey="Visanji N" first="Naomi P." last="Visanji">Naomi P. Visanji</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001413 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001413 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:20FC845813D16900FCBEF3A57D8CB14CAA08AEB2
|texte= Increased levels of 5‐HT1A receptor binding in ventral visual pathways in Parkinson's disease
}}
| This area was generated with Dilib version V0.6.29. |  |